XNAS · Healthcare · Biotechnology
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | -0.53 | -0.48 | +9.43% | $0 | ✅ Beat | +0.00% | -3.97% | — |
| 2026-03-12 | Q4 2025 | -0.61 | -0.45 | +26.23% | $0 | ✅ Beat | +0.16% | +21.35% | +86.25% |
| 2025-11-12 |
| Q3 2025 |
| -0.54 |
| -0.55 |
| -1.85% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.45 | -0.46 | -2.22% | $0 | ❌ Miss | +0.61% | +16.86% | +20.84% |
| 2025-03-06 | Q4 2024 | -0.98 | -0.49 | +50.00% | $0 | ✅ Beat | +3.87% | +10.63% | -24.33% |
| 2024-11-13 | Q3 2024 | -0.40 | -1.46 | -265.00% | $0 | ❌ Miss | -6.43% | -13.45% | -14.46% |
Showing last 6 quarters.